Cytek Biosciences, Inc. (CTKB)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$4.73+2.38%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Improve operating income from -$18.5M in Q1: Operating income not reported.
Cytek aims for $205M to $212M revenue in 2026. Revenue grew 6% last year. The company is improving sales despite losses. New products support future growth.
Cytek lost $18.5M operating income in Q1. Revenue fell from $62M to $44M. Key executives left recently. These hurt growth and profits.
The price is about 37% below our fair value near $7. Analysts expect 6% revenue growth. The market prices in a slow recovery.
Breaks if: Gross profit falls below $21.3M quarterly in 2026
Breaks if: Operating loss worsens beyond -$18.5M in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CTKB represents a speculative growth investment with a medium confidence level. The company is currently navigating through a period of mixed management execution and recent financial struggles, making its long-term thesis uncertain.
The market appears to price in a justified valuation, though CTKB is considered expensive compared to its peers. There is a low expectations gap, suggesting that investors may not anticipate significant positive changes in the near term.
Management has reaffirmed revenue guidance for 2026, but recent financial performance has been weak, with a notable risk of missing expectations. The company is also on a run of consecutive earnings misses, which adds to the uncertainty.
The future performance of CTKB hinges on its ability to meet revenue guidance and expand its installed base of instruments. Additionally, broader sector momentum from leading healthcare companies could provide support, while any negative shifts in the economy or company-specific issues could weigh heavily on its performance.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has put pressure on the thesis. Recent financial performance remains weak, with losses continuing to grow. This situation raises concerns about the company's credibility and outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on reducing operating losses and improving profitability through expense management and revenue growth.
Stated as a priority in 3 of last 3 quarters. Operating losses increased from $10.6 million in 2025-Q2 to $11.4 million in 2026-Q2, and from $15.0 million in 2025-Q1 to $18.5 million in 2026-Q1, indicating operating income has declined despite management focus. The trajectory shows limited progress on improving operating income.
“Loss from operations in the second quarter of 2026 was $11.4 million compared to loss of $10.6 million in 2025-Q2”
“Loss from operations in the first quarter of 2026 was $18.5 million compared to $15.0 million in 2025-Q1”
“Loss from operations in the fourth quarter of 2025 was $5.6 million compared to income of $3.0 million in 2024-Q4”
Breaks if: Annual revenue falls below $205M in 2026
In the next 1 to 3 years, CTKB's outlook is clouded by recent challenges and elevated risks, but sector dynamics may offer some support. Not investment advice.